​

Spyre Therapeutics (SYRE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SYRE Stock Forecast

Spyre Therapeutics (SYRE) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $53.67, with a high of $71.00 and a low of $40.00. This represents a 145.07% increase from the last price of $21.90.

$20 $31 $42 $53 $64 $75 High: $71 Avg: $53.67 Low: $40 Last Closed Price: $21.9

SYRE Stock Rating

Spyre Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

SYRE Forecast vs Benchmarks

TypeNameUpside
StockSpyre Therapeutics145.07%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$71.00$50.25
Last Closing Price$21.90$21.90$21.90
Upside/Downside-224.20%129.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-101--11
Dec, 24-101--11
Nov, 24610---16
Oct, 24610---16
Sep, 24610---16
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Alex ThompsonStifel Nicolaus$71.00$35.5299.89%224.20%
Oct 17, 2024Colleen KusyRobert W. Baird$50.00$32.3754.46%128.31%
Oct 15, 2024Yanan ZhuWells Fargo$40.00$30.6630.46%82.65%
May 10, 2024Julian HarrisonBTIG$40.00$35.1913.67%82.65%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024Wells FargoOverweightOverweighthold
Oct 14, 2024Cowen & Co.BuyBuyhold
Sep 25, 2024BTIGBuyBuyhold
Sep 03, 2024WedbushOutperforminitialise
Jul 16, 2024Evercore ISIOutperforminitialise
May 10, 2024BTIGBuyBuyhold
Mar 01, 2024Wells FargoOverweightupgrade

Financial Forecast

EPS Forecast

$-50 $-40 $-30 $-20 $-10 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-25.02$-24.86$-49.12-----
Avg Forecast$-24.97$-26.92$-7.51$-4.27$-3.86$-4.15$-4.74$-4.32
High Forecast$-24.97$-26.92$-7.51$-4.52$-4.49$-5.66$-6.61$-4.32
Low Forecast$-24.97$-26.92$-7.51$-3.98$-3.05$-2.62$-2.58$-4.32
Surprise %0.20%-7.65%554.06%-----

Revenue Forecast

$0 $4M $8M $12M $16M $20M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.74M$2.33M$886.00K-----
Avg Forecast$18.36M$2.23M$1.12M$2.99M$4.70M$166.67K$136.21K$85.29K
High Forecast$18.36M$2.23M$1.06M$2.99M$4.70M$166.67K$136.21K$85.29K
Low Forecast$18.36M$2.23M$1.18M$2.99M$4.70M$166.67K$136.21K$85.29K
Surprise %2.05%4.42%-20.69%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.80M$-83.81M$-338.79M-----
Avg Forecast$-172.21M$-185.65M$-55.11M$-31.21M$-27.67M$-30.37M$-33.75M$-31.73M
High Forecast$-172.21M$-185.65M$-55.11M$-33.21M$-32.97M$-41.53M$-48.54M$-31.73M
Low Forecast$-172.21M$-185.65M$-55.11M$-29.21M$-22.38M$-19.21M$-18.96M$-31.73M
Surprise %-61.79%-54.85%514.76%-----

SYRE Forecast FAQ

Is Spyre Therapeutics stock a buy?

Spyre Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spyre Therapeutics is a favorable investment for most analysts.

What is Spyre Therapeutics's price target?

Spyre Therapeutics's price target, set by 5 Wall Street analysts, averages $53.67 over the next 12 months. The price target range spans from $40 at the low end to $71 at the high end, suggesting a potential 145.07% change from the previous close price of $21.9.

How does Spyre Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Spyre Therapeutics stock forecast shows a 145.07% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Spyre Therapeutics over the past three months?

  • January 2025: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 90.91% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Spyre Therapeutics’s EPS forecast?

Spyre Therapeutics's average annual EPS forecast for its fiscal year ending in December is -4.27 for 2024, a -91.31% decrease from the reported $-49.12 in 2023. The prediction for 2025 is $-3.86, $-4.15 for 2026, $-4.74 for 2027, and $-4.32 for 2028.

What is Spyre Therapeutics’s revenue forecast?

Spyre Therapeutics's average annual revenue forecast for its fiscal year ending in December is $2.99M for 2024, a 236.99% increase from the reported $886K in 2023. The forecast for 2025 is $4.7M, $166.67K for 2026, $136.21K for 2027, and $85.29K for 2028.

What is Spyre Therapeutics’s net income forecast?

For its fiscal year ending in December, Spyre Therapeutics's average annual net income forecast is $-31.212M for 2024, reflecting a -90.79% decrease from the reported $-339M in 2023. The projection for 2025 is $-27.674M, $-30.37M for 2026, $-33.75M for 2027, and $-31.728M for 2028.